Alnylam Pharmaceuticals Files 8-K on Shareholder Votes
Ticker: ALNY · Form: 8-K · Filed: May 20, 2024 · CIK: 1178670
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: ALNY
TL;DR
ALNY filed an 8-K for shareholder votes. Nothing major to see here.
AI Summary
Alnylam Pharmaceuticals, Inc. filed an 8-K on May 20, 2024, reporting on matters submitted to a vote of security holders as of May 16, 2024. The filing details the company's principal executive offices located at 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142.
Why It Matters
This filing indicates that Alnylam Pharmaceuticals held a shareholder vote, which is a routine but important event for corporate governance and transparency.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for a shareholder vote, not indicating any immediate financial or operational risks.
Key Players & Entities
- Alnylam Pharmaceuticals, Inc. (company) — Filer of the 8-K
- May 20, 2024 (date) — Date of Report
- May 16, 2024 (date) — Date of earliest event reported
- 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on matters submitted to a vote of security holders.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 16, 2024.
What is the address of Alnylam Pharmaceuticals, Inc.'s principal executive offices?
The address of Alnylam Pharmaceuticals, Inc.'s principal executive offices is 675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142.
What is the Commission File Number for Alnylam Pharmaceuticals, Inc.?
The Commission File Number for Alnylam Pharmaceuticals, Inc. is 001-36407.
What is the IRS Employer Identification Number for Alnylam Pharmaceuticals, Inc.?
The IRS Employer Identification Number for Alnylam Pharmaceuticals, Inc. is 77-0602661.
Filing Stats: 652 words · 3 min read · ~2 pages · Grade level 8.6 · Accepted 2024-05-20 16:34:56
Key Financial Figures
- $0.01 — ange on Which Registered Common Stock, $0.01 par value per share ALNY The Nasdaq Sto
Filing Documents
- alny-20240516.htm (8-K) — 44KB
- 0001178670-24-000027.txt ( ) — 169KB
- alny-20240516.xsd (EX-101.SCH) — 2KB
- alny-20240516_lab.xml (EX-101.LAB) — 22KB
- alny-20240516_pre.xml (EX-101.PRE) — 13KB
- alny-20240516_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders The 2024 Annual Meeting of Stockholders (the "Annual Meeting") of Alnylam Pharmaceuticals, Inc. (the "Company") was held on May 16, 2024. As of March 22, 2024, the record date for the Annual Meeting, 126,452,099 shares of the Company's common stock were issued and outstanding. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. 1. The Company's stockholders re-elected the four persons listed below as Class II directors, each to serve until the Company's 2027 annual meeting of stockholders or until his successor is duly elected and qualified. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes Dennis A. Ausiello, M.D. 103,971,532 8,960,235 14,285 4,991,057 Olivier Brandicourt, M.D. 106,444,201 6,487,472 14,379 4,991,057 Peter N. Kellogg 108,577,015 4,354,577 14,460 4,991,057 David E.I. Pyott 102,273,209 10,658,278 14,565 4,991,057 The terms of office of the following directors continued after the Annual Meeting: Carolyn R. Bertozzi, M.D. Michael W. Bonney Yvonne L. Greenstreet, MBChB Margaret A. Hamburg, M.D. Colleen F. Reitan Amy W. Schulman Phillip A. Sharp, Ph.D. Elliott Sigal, M.D., Ph.D. 2. The Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 106,783,262 6,133,628 29,162 4,991,057 3. The Company's stockholders ratified the appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2024. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 114,460,115 3,456,326 20,668 0
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 20, 2024 ALNYLAM PHARMACEUTICALS, INC. By: /s/ Jeffrey V. Poulton Jeffrey V. Poulton Executive Vice President, Chief Financial Officer